Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]

Anónimo. Etravirine et HIV chez les enfants de plus de 6 ans. Prescrire 2014;34:416. [Ref.ID 97946]

Anónimo. Dolutégravir. Prescrire 2014;34:414-5. [Ref.ID 97945]

Anónimo. Raltégravir et HIV chez les enfants de plus de 2 ans. Prescrire 2014;34:413. [Ref.ID 97944]

Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014;384:258-71. [Ref.ID 97821]

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbel TB, Sax PE, Gulick RM, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014;161:1-10. [Ref.ID 97795]

Anónimo. Elvitegravir/cobicistat/emtricitabina/tenofovir. Stribild (Gilead). Infección por VIH. PAM 2014;38:39-48. [Ref.ID 97722]

ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014;383:1474-82. [Ref.ID 97538]

Anónimo. Dolutegravir (Tivicay) for HIV. Med Lett Drugs Ther 2013;55:77-9. [Ref.ID 96249]

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, on behalf of the SRPING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43. [Ref.ID 95046]

Waters LJ, Barber TJ. Dolutegravir for treatment of HIV: SPRING forwards?. Lancet 2013;381:705-6. [Ref.ID 95045]

Török ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med 2011;365:1538-40. [Ref.ID 91585]

Karim SSA, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jihoo N, Nair G, El-Sadr WM, Friedland G, Karim QA. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501. [Ref.ID 91584]

Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, for the AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91. [Ref.ID 91583]

Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy J-F, Goldfeld AE, for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81. [Ref.ID 91582]

The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170:410-9. [Ref.ID 88063]

de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions. A meta-analysis of randomized controlled trials. Arch Intern Med 2010;170:240-50. [Ref.ID 87849]

Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]

Emery S, Winston A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009;374:764-6. [Ref.ID 86736]

Volari A, Paed MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA, for the CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44. [Ref.ID 84525]